Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection

Table 6 Univariate and multivariate analysis to evaluate each variable and medication for the risk of chronic non HBV/HCV hepatitis***

Clinical parameters and ARV	Univariate	p value*	Multivariate	p value**
	OR (95% CI)		AOR (95% CI)
Male sex	3.0(1.6–5.5)	<0.001	3.1(1.5–6.3)	0.002*
BMI ≥ 23 kg/m2 at time of ALT elevation	3.1(1.7–5.6)	<0.001	2.4(1.2–4.8)	0.01*
Metabolic syndrome at baseline visit	4.0(0.8–18.8)	0.08
Plasma HIV-1 RNA level ≥ 5 log 10 copies/ml at baseline visit	1.6(0.9–3.0)	0.13
HDL cholesterol ≤ 40 mg/dL (male) or ≤ 50 mg/dL (female) at time of ALT elevation	1.8(0.9–3.7)	0.09
Exposure to NNRTIs + boosted PIs regimens	0.3(0.1–1.4)	0.12

Abbreviation: OR Odds ratio, AOR Adjusted odds ratio, BMI Body mass index, HDL High density lipoprotein, NNRTI Non-nucleoside reverse transcriptase inhibitor, PIs Protease inhibitors,
*P value less than 0.20 from univariate analysis to the model for multivariable analysis **Significant value with p value less than 0.05.
*** Chronic hepatitis was defined as those with elevated ALT ≥ 40 IU/L at 2 consecutive visits 6 months apart.

ISSN: 1742-6405